


**Product Name: Recombinant Human KNG1 (C-6His)**  
**Catalog #: PHH1047**



## Summary

<b>Name</b>	Kininogen
<b>Purity</b>	Greater than 95% as determined by reducing SDS-PAGE
<b>Endotoxin level</b>	<1 EU/μg as determined by LAL test.
<b>Construction</b>	Recombinant Human Kininogen-1 is produced by our Mammalian expression system and the target gene encoding Gln19-Ser427 is expressed with a 6His tag at the C-terminus.
<b>Accession #</b>	P01042-2
<b>Host</b>	Human Cells
<b>Species</b>	Human
<b>Predicted Molecular Mass</b>	46.89 KDa
<b>Formulation</b>	Lyophilized from a 0.2 μm filtered solution of 20mM Hac-NaAC, 150mM NaCl, pH 4.0.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
<b>Stability&amp;Storage</b>	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
<b>Reconstitution</b>	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

## SDS-PAGE image



## Background

**Product Name: Recombinant Human KNG1 (C-6His)**  
**Catalog #: PHH1047**

---



**Alternative Names**

Kininogen-1; Ipha-2-Thiol Proteinase Inhibitor; Fitzgerald Factor; High Molecular Weight Kininogen; HMWK; Williams-Fitzgerald-Flaujeac Factor; KNG1; BDK; KNG

**Background**

Kininogen-1 is a secreted protein which contains three cystatin domains. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms. Kininogen-1 plays a critical role in blood coagulation and inflammatory response. Kininogens are inhibitors of thiol proteases. Kininogen-1 participates in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, also inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. The active peptide bradykinin that is released from Kininogen-1 shows a variety of physiological effects: influence in smooth muscle contraction, induction of hypotension, natriuresis and diuresis, decrease in blood glucose level. It is a mediator of inflammation and causes increase in vascular permeability, stimulation of nociceptors release of other mediators of inflammation. It has a cardioprotective effect. LMW-kininogen inhibits the aggregation of thrombocytes and doesn't involved in blood clotting.

**Note**

For Research Use Only , Not for Diagnostic Use.